CN112587646A - Traditional Chinese medicine composition for aiding sleep - Google Patents
Traditional Chinese medicine composition for aiding sleep Download PDFInfo
- Publication number
- CN112587646A CN112587646A CN202110032699.XA CN202110032699A CN112587646A CN 112587646 A CN112587646 A CN 112587646A CN 202110032699 A CN202110032699 A CN 202110032699A CN 112587646 A CN112587646 A CN 112587646A
- Authority
- CN
- China
- Prior art keywords
- extract
- percent
- sleep
- mass
- main raw
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 230000007958 sleep Effects 0.000 title claims abstract description 44
- 239000003814 drug Substances 0.000 title claims abstract description 28
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 73
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 43
- 239000002994 raw material Substances 0.000 claims abstract description 41
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 37
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 36
- 235000020689 passion flower extract Nutrition 0.000 claims abstract description 26
- 229940001884 passion flower extract Drugs 0.000 claims abstract description 26
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 25
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 25
- 241000222336 Ganoderma Species 0.000 claims abstract description 23
- 244000062730 Melissa officinalis Species 0.000 claims abstract description 22
- 235000010654 Melissa officinalis Nutrition 0.000 claims abstract description 20
- 229940094952 green tea extract Drugs 0.000 claims abstract description 19
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 19
- 229940002508 ginger extract Drugs 0.000 claims abstract description 18
- 235000020708 ginger extract Nutrition 0.000 claims abstract description 18
- 229940026510 theanine Drugs 0.000 claims abstract description 18
- 229940026314 red yeast rice Drugs 0.000 claims abstract description 17
- 235000013616 tea Nutrition 0.000 claims abstract description 12
- 244000269722 Thea sinensis Species 0.000 claims abstract description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 36
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 18
- 239000004386 Erythritol Substances 0.000 claims description 18
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 18
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 18
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 18
- 235000019414 erythritol Nutrition 0.000 claims description 18
- 229940009714 erythritol Drugs 0.000 claims description 18
- 239000000905 isomalt Substances 0.000 claims description 18
- 235000010439 isomalt Nutrition 0.000 claims description 18
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 18
- 235000019359 magnesium stearate Nutrition 0.000 claims description 18
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 18
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 18
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 18
- 240000008866 Ziziphus nummularia Species 0.000 claims description 13
- 240000008397 Ganoderma lucidum Species 0.000 claims description 12
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 12
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 claims description 9
- 229930003944 flavone Natural products 0.000 claims description 8
- 235000011949 flavones Nutrition 0.000 claims description 8
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims description 8
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 claims description 7
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- 229930182490 saponin Natural products 0.000 claims description 7
- 235000017709 saponins Nutrition 0.000 claims description 7
- 150000007949 saponins Chemical class 0.000 claims description 7
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 claims description 7
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 claims description 7
- 229940057948 magnesium stearate Drugs 0.000 claims description 6
- 150000002213 flavones Chemical class 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 241000282414 Homo sapiens Species 0.000 abstract description 23
- 239000000463 material Substances 0.000 abstract description 15
- 230000006870 function Effects 0.000 abstract description 14
- 230000001105 regulatory effect Effects 0.000 abstract description 11
- 238000011160 research Methods 0.000 abstract description 6
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 230000008844 regulatory mechanism Effects 0.000 abstract description 2
- 210000001835 viscera Anatomy 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 40
- 238000012360 testing method Methods 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 15
- 230000004622 sleep time Effects 0.000 description 13
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 10
- 241001122767 Theaceae Species 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 210000003169 central nervous system Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000004620 sleep latency Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- 229960001412 pentobarbital Drugs 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 6
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 6
- 150000002212 flavone derivatives Chemical class 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000000147 hypnotic effect Effects 0.000 description 6
- 206010022437 insomnia Diseases 0.000 description 6
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 6
- 230000002936 tranquilizing effect Effects 0.000 description 6
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 229960000796 barbital sodium Drugs 0.000 description 5
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 5
- 229940125717 barbiturate Drugs 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000028527 righting reflex Effects 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 4
- 108010041191 Sirtuin 1 Proteins 0.000 description 4
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 210000004958 brain cell Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000932 sedative agent Substances 0.000 description 4
- 230000001624 sedative effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 description 3
- 244000288157 Passiflora edulis Species 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000517 effect on sleep Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 229940074968 melissa officinalis extract Drugs 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 230000003860 sleep quality Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 229940126673 western medicines Drugs 0.000 description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 2
- 108010060511 4-Aminobutyrate Transaminase Proteins 0.000 description 2
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 description 2
- 102100033639 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- 235000007189 Oryza longistaminata Nutrition 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 235000000370 Passiflora edulis Nutrition 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- SMRPGWBDLOQHOS-UHFFFAOYSA-N 5-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[[9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]oxane-2-carboxylic acid Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(C(O)C2O)C(O)=O)OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4=O)C)(C)CC3)(C)CC2)(C)CO)OC(CO)C(O)C1O SMRPGWBDLOQHOS-UHFFFAOYSA-N 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 241001506951 Alpinia nigra Species 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 102000017934 GABA-B receptor Human genes 0.000 description 1
- 108060003377 GABA-B receptor Proteins 0.000 description 1
- 241001489091 Ganoderma sinense Species 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000011925 Passiflora alata Nutrition 0.000 description 1
- 235000011922 Passiflora incarnata Nutrition 0.000 description 1
- 235000013750 Passiflora mixta Nutrition 0.000 description 1
- 235000013731 Passiflora van volxemii Nutrition 0.000 description 1
- 241001646828 Platostoma chinense Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- BMWPBKOFJSHJAW-UHFFFAOYSA-N Saponin B Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(OC7OC(CO)C(O)C(O)C7O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O BMWPBKOFJSHJAW-UHFFFAOYSA-N 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 206010043268 Tension Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 241000234314 Zingiber Species 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000005080 cortical synaptosome Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- -1 flavonoid compounds Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229940057059 monascus purpureus Drugs 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- PPRSVUXPYPBULA-UHFFFAOYSA-N saponin A Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O PPRSVUXPYPBULA-UHFFFAOYSA-N 0.000 description 1
- 229930193195 schizandrin Natural products 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The embodiment of the invention provides a traditional Chinese medicine composition for aiding sleep, which comprises the following main raw materials in percentage by mass: 24 to 27 percent of spina date seed extract, 9 to 11 percent of lucid ganoderma extract, 8.3 to 10 percent of schisandra extract, 4 to 5 percent of gamma-aminobutyric acid, 2.5 to 4.5 percent of theanine of tea leaves, 1.2 to 1.8 percent of melissa officinalis, 0.3 to 0.7 percent of passion flower extract, 27.5 to 29 percent of red yeast rice, 9.2 to 11 percent of green tea extract and 6 to 8 percent of black ginger extract. The embodiment of the invention provides a traditional Chinese medicine composition for assisting sleep, which starts from the research of a sleep-wake regulation mechanism from the receptor angle, starts from GABA regulation and control branches to regulate sleep, is assisted by traditional Chinese medicinal materials, and assists in regulating the operation of functions of various internal organs of a body from the traditional Chinese medicine theory angle to ensure that the operation of yin and yang qi of a human body is normal, thereby further regulating the sleep of the human body.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine health care, in particular to a traditional Chinese medicine composition for aiding sleep.
Background
With the social development, the pace of life is accelerated, night life is increased, the sleep time is shortened, the sleep quality is reduced due to various sleep diseases such as insomnia and snoring, and the sleep quality of people is worsened due to a plurality of factors such as further enhancement of work and employment pressure of people and competition pressure in various fields. Insufficient sleep can lead to memory loss and decreased brain function. The energy and oxygen in the brain nerve cells are greatly consumed in working and learning in the daytime, and the brain nerve cells can be in a rest state by enough sleep, so that the energy and the oxygen are supplemented, the memory is enhanced, the brain function is recovered, and the fatigue is eliminated. At present, medicines (western medicines) are mostly used for solving the sleep problem in the market, however, the traditional medicines for treating insomnia by using the western medicines, such as barbiturates, benzodiazepines and the like, are often accompanied by large side effects after being taken, such as hangover, addiction, rebound after stopping taking the medicines and the like. The traditional Chinese medicine has the advantages that western medicines do not exist, namely, the traditional Chinese medicine is not addicted and does not generate dependence, and people can be helped to realize natural and healthy sleep. Therefore, there is an urgent need for a Chinese medicinal product which has no side effects and can improve sleep quality.
Disclosure of Invention
The embodiment of the invention provides a traditional Chinese medicine composition for aiding sleep, which overcomes the defects of the prior art.
In order to achieve the purpose, the invention adopts the following technical scheme.
A traditional Chinese medicine composition for aiding sleep comprises the following main raw materials in percentage by mass: 24 to 27 percent of spina date seed extract, 9 to 11 percent of lucid ganoderma extract, 8.3 to 10 percent of schisandra extract, 4 to 5 percent of gamma-aminobutyric acid, 2.5 to 4.5 percent of theanine of tea leaves, 1.2 to 1.8 percent of melissa officinalis, 0.3 to 0.7 percent of passion flower extract, 27.5 to 29 percent of red yeast rice, 9.2 to 11 percent of green tea extract and 6 to 8 percent of black ginger extract.
Preferably, the content of total saponins in the spina date seed extract is more than or equal to 2%, the content of crude polysaccharide in the lucid ganoderma extract is more than or equal to 10%, the content of schizandrol A in the schisandra chinensis extract is more than or equal to 1.0%, and flavone in the passionflower extract calculated by vitexin is more than or equal to 4%.
Preferably, the wild jujube seed extract is 27%, the ganoderma lucidum extract is 9%, the schisandra chinensis extract is 8.3%, the gamma-aminobutyric acid is 5%, the theanine of tea is 4.5%, the melissa officinalis is 1.2%, the passion flower extract is 0.3%, the red yeast rice is 27.5%, the green tea extract is 9.2%, and the black ginger extract is 8%.
Preferably, the wild jujube seed extract is 24%, the ganoderma lucidum extract is 11%, the schisandra chinensis extract is 10%, the gamma-aminobutyric acid is 4%, the tea theanine is 2.5%, the melissa officinalis is 1.8%, the passion flower extract is 0.7%, the red yeast rice is 29%, the green tea extract is 11%, and the black ginger extract is 6%.
Preferably, the wild jujube seed extract is 25.75%, the ganoderma lucidum extract is 10.3%, the schisandra chinensis extract is 9.16%, the gamma-aminobutyric acid is 4.29%, the tea theanine is 2.86%, the melissa officinalis is 1.43%, the passion flower extract is 0.43%, the red yeast rice is 28.61%, the green tea extract is 10.3%, and the black ginger extract is 6.87%.
Preferably, the composition further comprises an auxiliary material, wherein the auxiliary material is one or more of isomalt, erythritol, microcrystalline cellulose and magnesium stearate;
when the composition contains isomalt, the isomalt accounts for 18-21% of the main raw material by mass;
when the composition contains erythritol, the erythritol accounts for 2.7-3% of the main raw material by mass;
when the composition contains microcrystalline cellulose, the mass percent of the microcrystalline cellulose in the main raw material is 2.5% -2.8%;
when the composition contains magnesium stearate, the magnesium stearate accounts for 0.5-0.65% of the main raw material by mass.
Preferably, the isomalt accounts for 19.69% of the main raw material by mass, the erythritol accounts for 2.86% of the main raw material by mass, the microcrystalline cellulose accounts for 2.63% of the main raw material by mass, and the magnesium stearate accounts for 0.57% of the main raw material by mass.
The embodiment of the invention provides a traditional Chinese medicine composition for aiding sleep, which has the following pharmacological actions:
1) wild jujube seed
Semen Ziziphi Spinosae is seed of Rhamnaceae plant fructus Ziziphi Spinosae, and semen Ziziphi Spinosae saponin A, B and flavonoid compounds in semen Ziziphi Spinosae are main effective components, and have tranquilizing and hypnotic effects. The spina date seed also has remarkable effects of reducing blood fat and resisting platelet aggregation; has effects in resisting myocardial ischemia and lipid peroxidation in rat. Animal experiments prove that the spina date seed can inhibit the central nervous system, has the effects of tranquilizing and hypnotizing and has no toxic reaction. The results of experiments on animals and human bodies show that the effects and the curative effects of the animals and the human bodies are completely the same, and the animals and the human bodies have no difference and no opposite effect of inducing awakening.
2) Schisandra chinensis
Fructus Schisandrae is fruit of Schisandra chinensis of Magnoliaceae. The pericarp and mature seed coat contain lignans, which are the effective medicinal components of fructus Schisandrae, including various schizandrin. Has obvious effects on central nervous system, and has effects of tranquilizing, invigorating qi, promoting fluid production, and treating cough, asthma, body fluid deficiency, xerostomia, spermatorrhea, chronic diarrhea, amnesia, insomnia, etc. Pharmacological tests prove that the Chinese medicinal composition can regulate the excitation and inhibition processes of the central nervous system, promote the metabolism of the human body, and has the effects of astringing, arresting discharge, tonifying qi, promoting the production of body fluid, tonifying the kidney and calming the heart. The Chinese medicinal composition is clinically applied to chronic cough and asthenic asthma, nocturnal emission, enuresis, frequent micturition, chronic diarrhea, spontaneous perspiration, night sweat, regular injury, thirst, palpitation and insomnia.
3) Glossy ganoderma
Ganoderma is whole plant of Ganoderma lucidum or Ganoderma sinense of Polyporaceae. Ganoderma lucidum has high medicinal value as a traditional Chinese treasure medicinal material with thousands of years of medicinal history, and the ancient China believes that the Ganoderma lucidum has the effects of being old and dead and reviving and is regarded as the Mesona chinensis. Modern pharmacological research of scientific research institutions for decades proves that the ganoderma lucidum has obvious curative effects on enhancing human immunity, regulating blood sugar, controlling blood pressure, assisting tumor radiotherapy and chemotherapy, protecting liver, promoting sleep and the like. The pharmacological actions of ganoderma lucidum are recognized and acknowledged internationally in many countries. In the future popularization process, the lucid ganoderma needs to obtain more cognition and application of people, and contributes to human health. Animal pharmacology shows that the experiment: ganoderma has effects of inhibiting nervous system, lowering blood pressure and strengthening heart contraction, and eliminating phlegm for respiratory system. Ganoderma lucidum has been used for neurasthenia and insomnia, and it has a good effect on the central nervous system. The extract can stimulate motility inhibition, reduce motility, cause coordinated movement disorder and show dosage-dependent disease-relieving effect, has effect in shortening sleep time for Cyclohexabarbital, and can prolong spasm and death time caused by central stimulant caffeine, and these results show that Ganoderma has inhibitory effect on central nervous system. The ganoderma lucidum has a strong regulating effect on the central nervous system, has the efficacy of tranquilizing and allaying excitement, is an essential good product for patients with neurasthenia and insomnia, and is an effective medicine for improving sleep and tranquilizing in the national formulary.
4) Gamma-aminobutyric acid
Gamma-aminobutyric acid (GABA) is a four-carbon nonprotein amino acid, is an important inhibitory neurotransmitter in the central nervous system of mammals and plays an important role in sleep. It can bind to and activate anxiolytic brain receptors, and then act synergistically with other substances to prevent anxiety-related information from reaching brain indicating center, thereby promoting relaxation and eliminating nervous tension, so as to achieve anti-stress and anxiolytic effects. The gamma-aminobutyric acid can rest the excited brain cells, inhibit the excessive excitation of nerve cells and achieve the effect of improving sleep. It is also called "natural sedative for the brain" because it can induce the brain to calm down.
GABA is a central nervous system inhibitory neurotransmitter, and can be catabolized via GABA bypass (GABA-shunt) under the action of GABA transaminase, and gamma-hydroxybutyric acid (GHB), an intermediate metabolite thereof, can exert inhibitory action on central nervous system excitatory neurons through the action of GHB specific receptors on cell membranes, GABA-B receptors or 5-hydroxytryptamine nervous systems and the like, thereby producing sedative and hypnotic effects on organisms.
The gamma-aminobutyric acid can promote the metabolism of brain tissues, recover the functions of brain cells and improve the nerve functions. It can enter into tricarboxylic acid circulation in brain to promote brain cell metabolism, raise glucose phosphatase activity during glucose metabolism, increase acetylcholine formation, dilate blood vessel, increase blood flow, make brain cell active and raise brain activity.
5) Theanine
Theanine is a unique amino acid found primarily in plants of the family Theaceae and typically constitutes 1-2% of the total weight of dry matter of tea. The theanine existing in nature is L-type, and is systematically named as: N-ethyl-L-glutamine, is very soluble in water. L-theanine can be absorbed through the small intestine wall, can pass through the blood brain barrier after a human body takes L-theanine for 30min, reaches the peak value of the L-theanine content in the brain after 5h, can influence the function of a central system through various mechanisms, and is metabolized in the spleen to generate ethylamine and glutamine.
6) Melissa officinalis
Melissa is also a species of mint, a traditional herb widely used as a mild sedative, spasmolytic, antibacterial agent. Animal experiments show that vanillin and citral are the main active components of Melissa officinalis with sedative and hypnotic effects. In addition, rosmarinic acid, ursolic acid and oleanolic acid in Melissa officinalis can inhibit GABA transaminase of brain tissue of rat, thereby interfering GABA metabolism, increasing GABA content in brain, reducing excitability of nervous system, tranquilizing, relieving and resisting anxiety.
Melissa extract also has a function of improving psychological mood and cognitive ability, and it is currently believed that these mechanisms are associated with muscarinic receptors and nicotinic acetylcholine receptors. The Melissa officinalis extract has acetylcholinesterase (AChE) inhibiting activity, and the acetylcholinesterase inhibitor can inhibit the activity of cholinesterase in synaptic cleft to reduce acetylcholine decomposition, thereby increasing acetylcholine activity to realize neuroprotection; melissa officinalis extract also has protective effect on methylenedioxymethamphetamine (MDMA) induced apoptosis of hippocampal primary neuronal cells.
7) Passion flower extract
In recent years, foreign research on the health care function of passion flower shows that the passion flower plant has the health care effects of resisting anxiety and calming and sleeping. The duration of sleep was significantly prolonged in mice in the ether-induced hypnotic test after addition of the water extract of passion fruit peel. The passion flower extract enhances the affinity to GABA receptors and inhibits the reuptake of rat cortical synaptosomes to GABA; direct GABA A current is induced in CA1 hippocampal pyramidal neurons, and the current has the function similar to benzodiazepine drugs.
8) Red rice
Red rice has effects of lowering blood pressure, reducing blood lipid, and reducing cholesterol, and the contained lovastatin can effectively prevent triglyceride formation. It also has effects in invigorating spleen, promoting digestion, promoting blood circulation, removing blood stasis, and has good adjuvant treatment effect on cardiovascular and cerebrovascular diseases, chest distress, headache, and abdominal distention.
9) Green tea extract
The green tea extract is an active component extracted from green tea leaves, mainly comprises tea polyphenol which has the effects of resisting oxidation, eliminating free radicals and the like, obviously reduces the content of serum total cholesterol, triglyceride and low-density lipoprotein cholesterol of hyperlipidaemia, simultaneously has the effects of recovering and protecting the function of vascular endothelium, improves the overall immunity of a human body and can promote the self-conditioning function of the human body.
10) Black ginger extract
The black ginger can be made into tea and various foods in folk, and is used for improving blood flow and enhancing vitality. Polymethoxylated flavones (PMFs) in the extract of Zingiber nigrum L have high activity on SIRT1 enzyme (deacetylase), and can activate SIRT1 enzyme. The SIRT1 enzyme can delay the onset of diseases caused by aging, such as diabetes, dementia, obesity, motor dysfunction and prolong the health span of human beings. The activation effect of the black ginger extract (100ug/mL) on the SIRT1 enzyme is 5 times that of resveratrol.
According to the technical scheme provided by the embodiment of the invention, the sleep-aiding traditional Chinese medicine composition is composed of traditional Chinese medicines such as a spina date seed extract, a lucid ganoderma extract, a schisandra chinensis extract, gamma-aminobutyric acid, tea theanine, melissa officinalis, a passion flower extract, red yeast rice, a green tea extract and a black ginger extract, and has the functions of soothing the nerves, aiding sleep, regulating blood pressure, enhancing human immunity and the like. The invention starts from the research of a sleep-wake regulation mechanism from the receptor perspective, starts from the GABA regulation branch to regulate the sleep, simultaneously assists with traditional Chinese medicinal materials, and assists in regulating the operation of the functions of various viscera of a human body from the traditional Chinese medicine theory perspective, so that the operation of yin and yang qi of the human body is normal, the sleep of the human body is further regulated, the sleep improvement effect is obvious, the safety is high, and no side effect exists; the red yeast, the green tea extract and the black ginger extract have the effects of being beneficial to regulating blood index levels such as blood fat, blood sugar and the like, can effectively improve the blood health condition of organisms, and increase the blood and nutrient supply capacity, thereby assisting in improving the sleep condition of the organisms; in addition, the melissa officinalis and the passion flower extract act on different aspects of GABA paths in GABA branches, so that the GABA content and the receptor affinity in a human body can be improved, a synergistic effect is achieved, and the dosage of gamma-aminobutyric acid in the composition can be reduced to a certain extent, so that the production cost is reduced.
Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention.
Detailed Description
In order to facilitate understanding of the embodiments of the present invention, the following description will be made by taking several specific embodiments as examples, and the embodiments are not to be construed as limiting the embodiments of the present invention.
The embodiment of the invention provides a traditional Chinese medicine composition for aiding sleep, which comprises the following main raw materials in percentage by mass: 24 to 27 percent of spina date seed extract, 9 to 11 percent of lucid ganoderma extract, 8.3 to 10 percent of schisandra extract, 4 to 5 percent of gamma-aminobutyric acid, 2.5 to 4.5 percent of theanine of tea leaves, 1.2 to 1.8 percent of melissa officinalis, 0.3 to 0.7 percent of passion flower extract, 27.5 to 29 percent of red yeast rice, 9.2 to 11 percent of green tea extract and 6 to 8 percent of black ginger extract.
Wherein, the content of total saponins in the wild jujube seed extract is more than or equal to 2 percent, the content of crude polysaccharide in the lucid ganoderma extract is more than or equal to 10 percent, the content of schizandrol A in the schisandra chinensis extract is more than or equal to 1.0 percent, and the content of flavone in the passionflower extract calculated by vitexin is more than or equal to 4 percent.
The composition also comprises an auxiliary material, wherein the auxiliary material is one or more of isomalt, erythritol, microcrystalline cellulose and magnesium stearate. When the composition contains isomalt, the isomalt accounts for 18-21% of the main raw material by mass, and is preferably 19.69%; when the composition contains erythritol, the erythritol accounts for 2.7-3% of the main raw material by mass, and preferably 2.86%; when the composition contains microcrystalline cellulose, the mass percent of the microcrystalline cellulose in the main raw material is 2.5-2.8%, preferably 2.63%; when the composition contains magnesium stearate, the mass percentage of the magnesium stearate in the main raw material is 0.5-0.65%, and preferably 0.57%.
According to the technical scheme, the GABA regulating branch is used for regulating the sleep, and the traditional Chinese medicine theory is combined with the traditional Chinese medicine theory and the traditional Chinese medicinal materials such as the spina date seed extract, the lucid ganoderma extract and the schisandra chinensis extract are used as auxiliary materials, so that the sleep of a human body is further regulated, and the sleep improving effect is obvious. The melissa officinalis and passion flower extract act on different aspects of GABA paths in GABA branches, can improve GABA content and receptor affinity in a human body, has a synergistic effect, and can reduce the dosage of gamma-aminobutyric acid in the composition to a certain extent, so that the production cost is reduced. In addition, the red yeast rice can generate a plurality of metabolites beneficial to human beings, and the red yeast rice and other medicinal materials in the composition supplement each other in action, so that the composition has a synergistic effect, and can effectively relieve emotion and improve sleep; green tea extract can improve cerebral cortex activity and regulate blood lipid metabolism; the extract of Zingiber Officinale Rosc has effects in improving sugar and lipid metabolism, inhibiting fat tissue hypertrophy, promoting muscle cell differentiation, improving blood vessel aging and blood flow, enhancing activity, and resisting saccharification and oxidation. The extract and the raw material composition have simple components, no side effect on human bodies and safety.
The embodiment of the invention provides a specific preparation process of a traditional Chinese medicine composition for aiding sleep, which is a known technology in the art, and is not described in detail in this embodiment and other embodiments.
In order to further explain the invention, the following describes the sleep-aiding Chinese medicinal composition provided by the invention in detail with reference to the examples.
Example one
In the embodiment of the invention, the traditional Chinese medicine composition for aiding sleep comprises the following main raw materials in percentage by mass: 27% of spina date seed extract, 9% of lucid ganoderma extract, 8.3% of schisandra extract, 5% of gamma-aminobutyric acid, 4.5% of theanine, 1.2% of melissa officinalis, 0.3% of passion flower extract, 27.5% of red yeast rice, 9.2% of green tea extract and 8% of black ginger extract. Wherein, the content of total saponins in the wild jujube seed extract is more than or equal to 2 percent, the content of crude polysaccharide in the lucid ganoderma extract is more than or equal to 10 percent, the content of schizandrol A in the schisandra chinensis extract is more than or equal to 1.0 percent, and the content of flavone in the passionflower extract calculated by vitexin is more than or equal to 4 percent.
The auxiliary materials in the composition are isomalt, erythritol, microcrystalline cellulose and magnesium stearate, wherein the isomalt accounts for 19.69% of the main raw material by mass, the erythritol accounts for 2.86% of the main raw material by mass, the microcrystalline cellulose accounts for 2.63% of the main raw material by mass, and the magnesium stearate accounts for 0.57% of the main raw material by mass.
Example two
In the embodiment of the invention, the traditional Chinese medicine composition for aiding sleep comprises the following main raw materials in percentage by mass: 24% of spina date seed extract, 11% of lucid ganoderma extract, 10% of schisandra extract, 4% of gamma-aminobutyric acid, 2.5% of theanine, 1.8% of melissa officinalis, 0.7% of passion flower extract, 29% of red yeast rice, 11% of green tea extract and 6% of black ginger extract. Wherein, the content of total saponins in the wild jujube seed extract is more than or equal to 2 percent, the content of crude polysaccharide in the lucid ganoderma extract is more than or equal to 10 percent, the content of schizandrol A in the schisandra chinensis extract is more than or equal to 1.0 percent, and the content of flavone in the passionflower extract calculated by vitexin is more than or equal to 4 percent.
The auxiliary materials in the composition are isomalt, erythritol, microcrystalline cellulose and magnesium stearate, wherein the isomalt accounts for 19.69% of the main raw material by mass, the erythritol accounts for 2.86% of the main raw material by mass, the microcrystalline cellulose accounts for 2.63% of the main raw material by mass, and the magnesium stearate accounts for 0.57% of the main raw material by mass.
EXAMPLE III
In the embodiment of the invention, the traditional Chinese medicine composition for aiding sleep comprises the following main raw materials in percentage by mass: 25.75% of spina date seed extract, 10.3% of lucid ganoderma extract, 9.16% of schisandra extract, 4.29% of gamma-aminobutyric acid, 2.86% of theanine, 1.43% of melissa officinalis, 0.43% of passion flower extract, 28.61% of red yeast rice, 10.3% of green tea extract and 6.87% of black ginger extract. Wherein, the content of total saponins in the wild jujube seed extract is more than or equal to 2 percent, the content of crude polysaccharide in the lucid ganoderma extract is more than or equal to 10 percent, the content of schizandrol A in the schisandra chinensis extract is more than or equal to 1.0 percent, and the content of flavone in the passionflower extract calculated by vitexin is more than or equal to 4 percent.
The auxiliary materials in the composition are isomalt, erythritol, microcrystalline cellulose and magnesium stearate, wherein the isomalt accounts for 19.69% of the main raw material by mass, the erythritol accounts for 2.86% of the main raw material by mass, the microcrystalline cellulose accounts for 2.63% of the main raw material by mass, and the magnesium stearate accounts for 0.57% of the main raw material by mass.
Example four
In the embodiment of the invention, the traditional Chinese medicine composition for aiding sleep comprises the following main raw materials: 225g of spina date seed extract, 90g of lucid ganoderma extract, 80g of schisandra chinensis extract, 37.5g of gamma-aminobutyric acid, 25g of theanine, 12.5g of melissa officinalis, 3.75g of passion flower extract, 250g of red yeast rice, 90g of green tea extract and 60g of black ginger extract. Wherein, the content of total saponins in the wild jujube seed extract is more than or equal to 2 percent, the content of crude polysaccharide in the lucid ganoderma extract is more than or equal to 10 percent, the content of schizandrol A in the schisandra chinensis extract is more than or equal to 1.0 percent, and the content of flavone in the passionflower extract calculated by vitexin is more than or equal to 4 percent.
The auxiliary materials comprise: 172g of isomalt, 25g of erythritol, 23g of microcrystalline cellulose and 5g of magnesium stearate.
EXAMPLE five
Animal experiments were carried out using the composition prepared in any of examples 1 to 4 above:
1. materials and methods
1.1 sample: tablet, size: 0.5 g/tablet, 2 tablets per person (adult) per day, wherein the recommended dosage for oral administration is 33.3mg/kg BW, and the weight of the adult is calculated according to 60 kg.
1.2 Experimental animals and groups: 120 SPF-grade healthy adult Kunming male mice bred in Guangdong province medical test animal center are selected, and the weight of the mice is 18-22 g. Every 40 mice are divided into one group, and 3 groups are respectively subjected to a direct sleep test, a test for prolonging the sleep time of pentobarbital sodium and a test for sleep latency of barbital sodium.
1.3 environmental conditions of experimental animal houses: animal laboratories are barrier systems. Laboratory temperature of the laboratory: 22-25 ℃, relative humidity: 55-77%.
1.4 dose selection and sample treatment: based on the recommended human dose for this sample, there were 3 test groups of 167, 333, 666mg/kg BW (corresponding to 5, 10, 20 times the recommended human dose), and one negative control group of 10 animals per group. Respectively weighing 835 mg, 1665 mg and 3330mg of the composition tablets, adding pure water to 100mL, mixing uniformly, preparing 8.35 mg/mL, 16.65 mg/mL and 33.30mg/mL concentration solutions, respectively feeding corresponding dose groups of animals with the gavage volume of 0.2mL/10g BW, feeding the control group with the pure water with the same volume, gavage once a day, and continuously gavage for 30 days.
1.5 Main instruments and reagents
The instrument comprises the following steps: animal platform scales, electronic analytical balances, stopwatches, and the like.
Reagent: pentobarbital sodium (imported and packaged by Shanghai West Biotech Co., Ltd.), and barbital sodium (produced by Guangfu Fine chemical research institute of Tianjin).
1.6 Experimental methods
1.6.1 direct sleep test: and (3) observing the sleep condition of the mouse after the last sample is given, judging that the mouse enters the sleep by taking the disappearance of the righting reflex of the animal for more than 60 seconds, and judging that the animal is awakened by the restoration of the righting reflex. Experimental results the number of animals falling asleep was measured as x2Testing, and statistically analyzing the sleep time by using analysis of variance. If the number of the animals falling asleep or the sleep time of the test group is increased and has a significant difference with the negative control group, the test result is judged to be positive.
1.6.2 test for prolonging the sleep time of sodium pentobarbital: after 20 minutes of administration of the last sample, animals were injected intraperitoneally with 45mg/kg BW of sodium pentobarbital in an amount of 0.2mL/20g BW. And observing whether the test object can prolong the sleep time of the sodium pentobarbital by taking the disappearance of the righting reflex of the animal as an index. The experimental results were statistically analyzed by analysis of variance. If the sleeping time of the test group mouse is longer than that of the negative control group and has statistical significance, the test result is judged to be positive.
1.6.3 barbiturate sodium sleep latency test: each group of animals was injected with 300mg/kg BW of barbital sodium intraperitoneally 20 minutes after the last sample administration, and the injection amount was 0.2mL/20g BW. And observing whether the test object can shorten the sleep latency of the barbiturate sodium by taking the disappearance of the righting reflex as an index. The experimental results were statistically analyzed by analysis of variance. If the sleep latency of the test group mice is shorter than that of the negative control group and has statistical significance, the test result is judged to be positive.
1.7 determination of results
If the test for prolonging the sleep time of the sodium pentobarbital and the test for prolonging the sleep latency of the sodium barbital are positive and have no obvious direct sleep effect, the test sample can be judged to have the effect of improving the sleep function.
2. Results
2.1 Effect of samples on mouse body weight
Note: in the sleep I-III groups, the initial, middle and terminal body weights and weight gains of mice in each dose group are compared with those in a negative control group, and the differences are not significant (P is more than 0.05).
As can be seen from Table 1, the body weights of the mice in each dose group of the samples at the initial stage, the middle stage and the final stage of the experiment and the body weight increase of the mice in the experiment period are compared with those of the negative control group, and the differences are not significant (P is more than 0.05), which indicates that the sample has no obvious influence on the body weight increase of the mice.
2.2 direct sleep Effect of samples
As can be seen from table 2, when the composition of the present invention is orally administered to mice at different doses for 30 days, no animal appears to have the disappearance of righting reflex in each dose group, i.e. all animals do not enter a sleep state, and the sample is promoted not to have the effect of directly inducing the sleep of the mice.
TABLE 2 direct sleep test results in mice
2.3 Effect of samples on sleep time of sodium pentobarbital
As can be seen from table 3, when the composition of the present invention is orally administered to mice at different doses for 30 days, the sleep time of each dose group is longer than that of the negative control group, and the difference between the high and medium dose groups and the negative control group is significant (P <0.01 and P <0.05, respectively), indicating that the sample has the effect of prolonging the sleep time of sodium pentobarbital.
2.4 Effect of samples on the hypnotic latency of barbiturate sodium
As can be seen from table 4, when the composition of the present invention is orally administered to mice at different doses for 30 days, the sleep latency of each dose group is shortened compared with that of the negative control group, and the difference between the high dose group and the negative control group is very significant (P <0.01), suggesting that the sample has the effect of shortening the sleep latency of barbital sodium.
3. Determination of results
The sleep-aiding traditional Chinese medicine composition provided by the embodiment of the invention with doses of 167, 333 and 666mg/kg BW (equivalent to 5, 10 and 20 times of the doses recommended by a human body) is continuously infused into a stomach of a mouse for 30 days, so that the sleep time of pentobarbital sodium can be prolonged, the sleep latency of the barbital sodium is shortened, a direct sleep effect is avoided, and the weight increase of the mouse is not obviously influenced, thereby prompting that the sample has the function of improving sleep.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope of the present invention are included in the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.
Claims (7)
1. The traditional Chinese medicine composition for aiding sleep is characterized by comprising the following main raw materials in percentage by mass: 24 to 27 percent of spina date seed extract, 9 to 11 percent of lucid ganoderma extract, 8.3 to 10 percent of schisandra extract, 4 to 5 percent of gamma-aminobutyric acid, 2.5 to 4.5 percent of theanine of tea leaves, 1.2 to 1.8 percent of melissa officinalis, 0.3 to 0.7 percent of passion flower extract, 27.5 to 29 percent of red yeast rice, 9.2 to 11 percent of green tea extract and 6 to 8 percent of black ginger extract.
2. The composition as claimed in claim 1, wherein the content of total saponins in the wild jujube seed extract is more than or equal to 2%, the content of crude polysaccharides in the ganoderma lucidum extract is more than or equal to 10%, the content of schizandrol A in the schisandra chinensis extract is more than or equal to 1.0%, and the content of flavones in the passionflower extract calculated by vitexin is more than or equal to 4%.
3. The composition of claim 2, wherein the wild jujube extract is 27%, the ganoderma extract is 9%, the schisandra extract is 8.3%, the gamma-aminobutyric acid is 5%, the theanine is 4.5%, the melissa officinalis is 1.2%, the passionflower extract is 0.3%, the red yeast rice is 27.5%, the green tea extract is 9.2%, and the black ginger extract is 8%.
4. The composition of claim 2, wherein the wild jujube extract is 24%, the ganoderma extract is 11%, the schisandra extract is 10%, the gamma-aminobutyric acid is 4%, the tea theanine is 2.5%, the lemon balm is 1.8%, the passion flower extract is 0.7%, the red yeast rice is 29%, the green tea extract is 11%, and the black ginger extract is 6%.
5. The composition of claim 2, wherein the amount of the wild jujube extract is 25.75%, the amount of the ganoderma lucidum extract is 10.3%, the amount of the schisandra chinensis extract is 9.16%, the amount of the gamma-aminobutyric acid is 4.29%, the amount of theanine is 2.86%, the amount of the melissa officinalis is 1.43%, the amount of the passion flower extract is 0.43%, the amount of the red yeast rice is 28.61%, the amount of the green tea extract is 10.3%, and the amount of the black ginger extract is 6.87%.
6. The composition according to any one of claims 1 to 5, further comprising an adjuvant, wherein the adjuvant is one or more of isomalt, erythritol, microcrystalline cellulose, and magnesium stearate;
when the composition contains isomalt, the isomalt accounts for 18-21% of the main raw material by mass;
when the composition contains erythritol, the erythritol accounts for 2.7-3% of the main raw material by mass;
when the composition contains microcrystalline cellulose, the mass percent of the microcrystalline cellulose in the main raw material is 2.5% -2.8%;
when the composition contains magnesium stearate, the magnesium stearate accounts for 0.5-0.65% of the main raw material by mass.
7. The composition according to claim 6, wherein the isomalt is 19.69% by mass of the main raw material, the erythritol is 2.86% by mass of the main raw material, the microcrystalline cellulose is 2.63% by mass of the main raw material, and the magnesium stearate is 0.57% by mass of the main raw material.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110032699.XA CN112587646A (en) | 2021-01-11 | 2021-01-11 | Traditional Chinese medicine composition for aiding sleep |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110032699.XA CN112587646A (en) | 2021-01-11 | 2021-01-11 | Traditional Chinese medicine composition for aiding sleep |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112587646A true CN112587646A (en) | 2021-04-02 |
Family
ID=75207040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110032699.XA Pending CN112587646A (en) | 2021-01-11 | 2021-01-11 | Traditional Chinese medicine composition for aiding sleep |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112587646A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114642258A (en) * | 2022-03-17 | 2022-06-21 | 无锡健特药业有限公司 | Beverage composition for relieving stress, relaxing mood and improving sleep of young people and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103340407A (en) * | 2013-07-23 | 2013-10-09 | 四川省中医药科学院 | Composition with sleep improving effect as well as preparation method and use of composition |
CN105770145A (en) * | 2016-03-15 | 2016-07-20 | 双飞人制药股份有限公司 | Medicinal composition with sleep improvement effect and preparation method for medicinal composition |
CN108210640A (en) * | 2018-04-09 | 2018-06-29 | 成都图径生物科技有限公司 | Alleviation visual fatigue composition containing tea extract |
-
2021
- 2021-01-11 CN CN202110032699.XA patent/CN112587646A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103340407A (en) * | 2013-07-23 | 2013-10-09 | 四川省中医药科学院 | Composition with sleep improving effect as well as preparation method and use of composition |
CN105770145A (en) * | 2016-03-15 | 2016-07-20 | 双飞人制药股份有限公司 | Medicinal composition with sleep improvement effect and preparation method for medicinal composition |
CN108210640A (en) * | 2018-04-09 | 2018-06-29 | 成都图径生物科技有限公司 | Alleviation visual fatigue composition containing tea extract |
Non-Patent Citations (2)
Title |
---|
王壮凌: "抒解抑郁症的草药", 《食品与健康》 * |
陈子彤 等: "酸枣仁、茶氨酸、γ-氨基丁酸联合使用改善睡眠作用研究", 《食品科技》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114642258A (en) * | 2022-03-17 | 2022-06-21 | 无锡健特药业有限公司 | Beverage composition for relieving stress, relaxing mood and improving sleep of young people and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Provino | The role of adaptogens in stress management | |
CN101716240A (en) | Preparation for improving sleep, replenishing qi and promoting blood generation | |
KR20100106976A (en) | Pharmaceutical compositions for treating depression and anxiety | |
CN104873745B (en) | A kind of Chinese medicine that treating insomnia and preparation method | |
CN108567889A (en) | A kind of Chinese medicine composition and the preparation method and application thereof of Effective Regulation sleep factors | |
CN107951953A (en) | A kind of kidney-tonifying and yang-strengthening medicinal liquor and preparation method thereof | |
CN102727761B (en) | Medicine for treating alopecia seborrheica and preventing hair drying and bifurcating and method for preparing medicine | |
CN104223297B (en) | A kind of schisandra chinensis health-care oral liquid of slow down aging and preparation method thereof | |
CN112587646A (en) | Traditional Chinese medicine composition for aiding sleep | |
CN104027428B (en) | Preparation method of traditional Chinese medicine compound and application of traditional Chinese medicine compound in prevention and treatment of senile dementia | |
CN102008083B (en) | Health food for alleviating physical fatigue and removing chloasma | |
CN109833381A (en) | A kind of pure plant drug composition improving sleep | |
KR20200087606A (en) | Compositions for Improving Memory Power and Learning Ability, and Relaxing stress | |
CN115487239A (en) | Pharmaceutical composition for treating insomnia with anxiety and depression and preparation method thereof | |
CN110960632B (en) | Formula of sleep improving product and preparation method thereof | |
CN111053854B (en) | Traditional Chinese medicine preparation with depression treatment effect and preparation method and application thereof | |
CN114010751A (en) | Chinese medicinal composition for preventing and treating cancer-induced fatigue and cancer-treated fatigue | |
CN108938764A (en) | It is a kind of to have effects that alleviate Chinese medicine composition of autonomic nervous dysfunction and preparation method thereof and product | |
CN112402569A (en) | Anti-fatigue health product and preparation method thereof | |
CN108014259B (en) | Traditional Chinese medicine composition for improving sleep and tablet thereof | |
CN105194355A (en) | Traditional Chinese medicine preparation for treating primary hypertension | |
CN106361976A (en) | Compound preparation for calming nerves, promoting sleep and keeping beauty and preparation method of compound preparation | |
US10744173B2 (en) | Traditional Chinese medicine compositions for alleviating stress | |
CN112843174A (en) | Traditional Chinese medicine composition with functions of tonifying spleen, nourishing heart and soothing nerves, preparation method and application | |
CN109200191A (en) | Restrain myogenic, Chinese materia medica preparation of light speckles, beautification and white and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |